News
![]() |
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 6, 2023
Receives regulatory approval from Health Canada to commence enrollment PARADIGM topline read-out expected H2 2023 CAMBRIDGE, Mass., Feb. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd....
-
Jan 19, 2023
Elevated levels of novel biomarker TDP-43 in Alzheimer's disease (AD) show the therapeutic potential of NeuroSense's combination platform Phase 2 double-blind proof-of-concept clinical study...
-
Dec 1, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended...
-
Nov 16, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian...
-
Nov 15, 2022
NeuroSense Therapeutics receives FDA clearance to commence patient enrollment in the U.S. with PrimeC, a novel combination therapy Follows a successful U.S. pharmacokinetic (PK) study which...
-
Oct 27, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences....
-
Oct 21, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe® Partnering...
-
Oct 18, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and released the video of Founder and...
-
Oct 12, 2022
Investors and analysts interested in participating in the Summit via webinar may register here: LINK CAMBRIDGE, Mass., Oct. 12, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)...
-
Sep 29, 2022
Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023 CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- NeuroSense...
-
Sep 28, 2022
Pharmacokineticic (PK) profile of PrimeC supports the formulation's extended release properties, as the active components are released simultaneously CAMBRIDGE, Mass., Sept. 28, 2022 /PRNewswire/...
-
Sep 21, 2022
Biomarker data to be presented provide indication of PrimeC's efficacy in ALS Phase IIb PARADIGM ALS trial's primary endpoints include biomarkers and ALS-related hallmarks Topline results expected...
-
Sep 20, 2022
PrimeC is safe and tolerable at over 4x the maximal clinical dose Data support current Phase IIb PARADIGM study design, new PrimeC formulation, and potential favorable clinical trial outcome...
-
Sep 19, 2022
Groundbreaking ALS biomarker research: Marks the first publication of NeuroSense's novel biomarker results demonstrating PrimeC's effect on ALS related hallmarks PrimeC showed a statistically...
-
Aug 31, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June...
-
Aug 2, 2022
- NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments - NeuroSense's CEO to present at EverythingALS's Expert Talk Series on...
-
Jul 28, 2022
NeuraLight's platform technology uses computer vision, artificial intelligence (AI), deep learning algorithms, and machine learning (ML) to identify and track oculometric digital biomarkers to...
-
Jul 18, 2022
View video here: https://youtu.be/KCT2wzOqmNo CAMBRIDGE, Mass., July 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe...
-
Jun 30, 2022
Biomarkers show the potential of NeuroSense's combination drug CogniC to treat Alzheimer's disease CogniC is expected to advance into clinical trials in 2023 CAMBRIDGE, Mass., June 30, 2022...
-
Jun 27, 2022
Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline...
-
Jun 22, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's...
-
Jun 1, 2022
Phase IIa study successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biomarkers PrimeC...
-
May 31, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the quarter ended March...
-
May 23, 2022
Ferenc Tracik, MD to deliver presentation - "From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS" Phase IIb ALS study for NeuroSense's combination...
-
Apr 11, 2022
Study conducted under FDA cleared protocol in parallel with international Phase IIb trial expected to commence in Q2 2022 CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- NeuroSense Therapeutics...